Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Other Accumulated Expenses (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Other Accumulated Expenses for 2 consecutive years, with $99898.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses changed N/A to $99898.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $99898.0, a N/A change, with the full-year FY2025 number at $278149.0, changed N/A from a year prior.
  • Other Accumulated Expenses was $99898.0 for Q4 2025 at Neuphoria Therapeutics, down from $112028.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $278149.0 in Q2 2025 to a low of $33306.0 in Q3 2024.